Advanced Prenatal Therapeutics, Inc. (APT)
APT is developing a patented medical device specifically designed to treat preeclampsia in pregnancy, a leading cause of maternal and fetal death worldwide.
APT is developing a Targeted Apheresis Column for Preeclampsia (TAC- PE) to be used to specifically and safely remove pathogenic factors associated with preeclampsia from the blood of pregnant mothers. Removing these factors could lead to prolonged pregnancy, improved fetal outcomes, and decreased risk associated with preterm birth. APT's TAC-PE could become the standard of care for treating this virtually unmet need.